Smyth, Laura J. http://orcid.org/0000-0001-6419-4826
Dahlström, Emma H. http://orcid.org/0000-0003-1271-8696
Syreeni, Anna http://orcid.org/0000-0003-1857-2560
Kerr, Katie
Kilner, Jill http://orcid.org/0000-0002-6020-4617
Doyle, Ross
Brennan, Eoin http://orcid.org/0000-0003-4908-5474
Nair, Viji
Fermin, Damian
Nelson, Robert G.
Looker, Helen C.
Wooster, Christopher http://orcid.org/0000-0002-0321-9556
Andrews, Darrell
Anderson, Kerry
McKay, Gareth J.
Cole, Joanne B. http://orcid.org/0000-0001-9520-2788
Salem, Rany M. http://orcid.org/0000-0001-8816-6862
Conlon, Peter J.
Kretzler, Matthias http://orcid.org/0000-0003-4064-0582
Hirschhorn, Joel N.
Sadlier, Denise
Godson, Catherine
Florez, Jose C. http://orcid.org/0000-0002-1730-9325
Forsblom, Carol http://orcid.org/0000-0002-3354-7454
Maxwell, Alexander P. http://orcid.org/0000-0002-6110-7253
Groop, Per-Henrik http://orcid.org/0000-0003-4055-6954
Sandholm, Niina http://orcid.org/0000-0003-4322-6942
McKnight, Amy Jayne http://orcid.org/0000-0002-7482-709X
,
Article History
Received: 27 April 2022
Accepted: 14 November 2022
First Online: 22 December 2022
Competing interests
: P.-H.G has received investigator-initiated research grants from Eli Lilly and Roche, is an advisory board member for AbbVie, Astellas, AstraZeneca, Boehringer Ingelheim, Cebix, Eli Lilly, Janssen, Medscape, Merck Sharp & Dohme, Mundipharma, Nestle, Novartis, Novo Nordisk and Sanofi; and has received lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Elo Water, Genzyme, Merck Sharp & Dohme, Medscape, Novartis, Novo Nordisk, PeerVoice and Sanofi. J.C.F. has received consulting honoraria from Goldfinch Bio and AstraZeneca, and speaker fees from Novo Nordisk, AstraZeneca, and Merck for research lectures over which the author had full control of content. J.N.H. hold equity in Camp4 Therapeutics. Dr. M. Kretzler reports grants and contracts outside the submitted work through the University of Michigan with NIH, Chan Zuckerberg Initiative, JDRF, AstraZeneca, NovoNordisk, Eli Lilly, Gilead, Goldfinch Bio, Janssen, Boehringer-Ingelheim, Moderna, European Union Innovative Medicine Initiative, Certa, Chinook, amfAR, Angion, RenalytixAI, Travere, Regeneron, IONIS; consulting fees through the University of Michigan from Astellas, Poxel and Janssen; and a patent PCT/EP2014/073413 “Biomarkers and methods for progression prediction for chronic kidney disease” licensed. R.M.S. receives funding from Travere Therapeutics. The funders listed had no role in any part of this study (design, data collection, management, analysis, interpretation, preparation, review or approval of the manuscript). The remaining authors declare no competing interests.